Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA in Newly Diagnosed AML
NCT00151242Phase 3Completed
- Sponsor
- Ulm University
- Start
- Jul 2004
- Primary completion
- Aug 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of tretinoin in acute myeloid leukemia (AML) (2 arms), sponsored by Ulm University. Primary endpoints: Complete Remission Rate, Relapse-Free Survival and 1 more. Started Jul 2004; status: completed.
02
Drugs
tretinoin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00151242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00151242.